Tscan therapeutics receives fda's regenerative medicine advanced therapy (rmat) designation for its two lead tcr-t therapy candidates for the treatment of heme malignancies

Rmat designation granted for both tsc-100 and tsc-101 for the treatment of patients with aml, all, and mds undergoing allogeneic hct with reduced intensity conditioning rmat designation granted for both tsc-100 and tsc-101 for the treatment of patients with aml, all, and mds undergoing allogeneic hct with reduced intensity conditioning
TCRX Ratings Summary
TCRX Quant Ranking